Kalaris Therapeutics (KLRS) Change in Accured Expenses (2019 - 2026)

Kalaris Therapeutics' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at $120000.0 for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 1600.0% year-over-year to $120000.0; the TTM figure through Mar 2026 stood at $2.3 million (up 6784.85% YoY), while the FY2025 annual figure was $2.1 million, up 1764.35% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $120000.0, down from $1.7 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $5.4 million in Q2 2023, with the low at -$13.8 million in Q1 2022.
• The 5-year median for Change in Accured Expenses is -$8000.0 (2025), against an average of -$750294.1.
• The sharpest annual moves came in 2022 and 2026: Change in Accured Expenses sank 935.52% in 2022, then soared 1600.0% in 2026.
• Kalaris Therapeutics' Change in Accured Expenses stood at -$1.7 million in 2022, then tumbled by 220.1% to -$5.6 million in 2023, then surged by 111.97% to $665000.0 in 2024, then surged by 159.4% to $1.7 million in 2025, then plunged by 93.04% to $120000.0 in 2026.
• Business Quant data shows KLRS's Change in Accured Expenses at $120000.0 in Q1 2026, $1.7 million in Q4 2025, and $151000.0 in Q3 2025.